



australasian society of clinical immunology and allergy

22 September 2021

Professor Andrew Wilson  
Chair, Pharmaceutical Benefits Advisory Committee (PBAC)  
MDP 952, GPO Box 9848  
Canberra, ACT 2601  
Email: [pbac@health.gov.au](mailto:pbac@health.gov.au)

Dear Professor Wilson,

**Re: Jorveza® (Budesonide) application for treatment of eosinophilic oesophagitis (EoE)**

Further to my letter of 10 February 2021, I write in support of this application on behalf of the eosinophilic oesophagitis (EoE) Working Party of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body of clinical immunology/allergy specialists in Australia and New Zealand.

This application for PBS listing of Jorveza® (Budesonide 1mg tablet for induction and maintenance and 0.5mg tablet for maintenance) is supported for the following reasons:

- EoE affects children and adults, and the frequency of EoE appears to be increasing.
- Untreated EoE can result in food impaction in the oesophagus, which may have to be removed in hospital. This can result in permanent scarring and narrowing of the oesophagus (stricture) and the need for dilatation (stretching) of the oesophagus.
- There are significant costs due to untreated EoE due to hospitalisation for removal of impacted food, medical consultations for poorly controlled disease and endoscopy for disease monitoring.
- Jorveza® (Budesonide as a dissolving oral tablet) is approved by the Therapeutic Goods Administration (TGA) for the treatment of EoE and is specifically formulated for EoE, to deliver the treatment directly to the inflammation within the oesophagus.
- PBS listing of Jorveza® (Budesonide) will improve access to effective therapeutic options for people with EoE, which is usually a lifelong disease that impacts on quality of life.
- If Jorveza® (Budesonide) is not PBS listed, people with EoE will be significantly disadvantaged compared to people with asthma, who can be prescribed Budesonide and other corticosteroid preventer therapies on the PBS.

We hope that the PBAC will take into account the reasons listed above, in support of the application for PBS listing of Jorveza® (Budesonide 0.5 and 1mg).

Please contact me by emailing [jill@allergy.org.au](mailto:jill@allergy.org.au) or phoning 0425216402 if you require more details.

Yours sincerely,

A handwritten signature in black ink that reads "Jill Smith". The signature is written in a cursive, flowing style.

Jill Smith  
ASCIA CEO